Please assess the completion status of the following clinical trial:

Trial Title: Novel Biomarkers for Invasive Aspergillosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 16y at start of study~* One of the following diagnoses:~* De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy~* De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy~* Aplastic anemia requiring ATG therapy~* Any patient admitted for either autologous or allogeneic hematopoietic stem cell transplantation~* Written informed consent obtained from the patient~Exclusion Criteria:~* AML or ALL beyond the specified inclusion criteria~* Directed treatment for possible, probable, or proven invasive aspergillosis, at moment of screening, or with end of treatment \< 6 weeks at screening, or no complete response according to EORTC/MSG criteria, or complete response achieved \< 6 weeks at time of screening.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total cohort (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).